BioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting NEW HAVEN, Conn., April 14, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive...

BioBlast Pharma Enhances Leadership Team NEW HAVEN, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare...